Portage

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

Retrieved on: 
Tuesday, November 28, 2023
PRTG, Adenosine, Lung cancer, ASCO, Research, Acquisition, Fiscal, D&O, Melanoma, Clinical trial, University, Calendar, MD Anderson Cancer Center, A2A, A2B, Patient, G&A, NSCLC, Portage, SITC, Pharmaceutical industry

WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.

Key Points: 
  • WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
  • “The Company is focused on developing its two lead clinical programs and maximizing its resources given market conditions.
  • Portage completed a $6 million financing in October 2023 for continued clinical development, general corporate and working capital purposes.
  • R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180%, for the Fiscal 2024 Quarter from approximately $1.5 million in the Fiscal 2023 Quarter.

Portage and Taktile Unveil the Top 50 US Fintechs Revolutionizing Business Finance and Lending in 2023

Retrieved on: 
Tuesday, December 12, 2023
Fintech, Professional Services, Business, Finance, Attention, Research, BNPL, Multimedia, Automation, Growth, AI, Friction, Bank, Sales, Marketing, B2B, Portage

Portage , a global investment platform in fintech and financial services, and Taktile , a risk decision engine provider, have identified the Top 50 US fintechs at the forefront of business finance and lending innovation in 2023.

Key Points: 
  • Portage , a global investment platform in fintech and financial services, and Taktile , a risk decision engine provider, have identified the Top 50 US fintechs at the forefront of business finance and lending innovation in 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231212944953/en/
    Portage and Taktile Unveil the Top 50 US Fintechs Revolutionizing Business Finance and Lending in 2023 (Graphic: Business Wire)
    This year, the B2B finance sector has seen considerable growth, with fintechs bringing game-changing products to the market, from embedded lending solutions to commercial credit cards.
  • Portage has been witnessing the rise of leading B2B fintechs, particularly in the United States.
  • The escalating demand for business credit is driving innovation in B2B solutions, creating a thriving subsector within the finance industry.

Croissant Launches Google Chrome Extension, Providing Shoppers with Guaranteed Buybacks™ of up to 75% on Over 1 Million Items at Major Fashion Brands and Retailers

Retrieved on: 
Wednesday, November 8, 2023
Technology, Fintech, Electronic Commerce, Specialty, Professional Services, Internet, Fashion, Retail, Online Retail, Sale, BoxGroup, KKR, Behavior, Data science, Nike, Multimedia, Chrome, Lululemon Athletica, Neiman Marcus, Portage, Google Chrome, Longevity, Online shopping, Guaranteed, Croissant

View the full release here: https://www.businesswire.com/news/home/20231108423741/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231108423741/en/
    Croissant launches Google Chrome extension, now providing shoppers with Guaranteed Buybacks™ on leading fashion sites.
  • (Graphic: Croissant)
    An industry first, Croissant’s offering allows customers to know the future resale value of items during the initial shopping journey.
  • Using Croissant’s Google Chrome extension, shoppers can opt into these Guaranteed Buybacks™ at no cost, and with no obligation to sell items later.
  • The new Google Chrome extension allows a wider range of customers and retailers to immediately benefit from Croissant’s unique value proposition.

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

Retrieved on: 
Wednesday, August 30, 2023
Neoplasm, UCSF Helen Diller Family Comprehensive Cancer Center, Portage, Thomas Jefferson University, Calendar, Clinical trial, USC Norris Comprehensive Cancer Center, Lead, G&A, Toxicity, Research, Lung cancer, ASCO, Adenosine, PRTG, Acquisition, American Society of Clinical Oncology, Patient, Washington University School of Medicine, A2A, Society, MD Anderson Cancer Center, Safety, Prostate cancer, Fiscal, Pharmaceutical industry, Coal, Taro (river)

WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.

Key Points: 
  • WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023.
  • R&D costs increased by approximately $1.7 million to approximately $3.6 million, or approximately 89%, for the Fiscal 2024 Quarter from approximately $1.9 million in the Fiscal 2023 Quarter.
  • G&A expenses decreased by approximately $0.8 million to approximately $1.4 million, or approximately 36%, from approximately $2.2 million in the Fiscal 2023 Quarter.
  • Professional fees decreased by $0.4 million, primarily attributable to legal fees associated with the Tarus acquisition in the Fiscal 2023 Quarter.

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

Retrieved on: 
Monday, June 26, 2023
KOL, University, Portage, Neoplasm, Clinical trial, Adenosine, PRTG, Patient, Immune system, MD Anderson Cancer Center, Safety, A2B, Prostate cancer, Pharmaceutical industry

The trial is evaluating Portage’s adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.

Key Points: 
  • The trial is evaluating Portage’s adenosine 2A receptor (A2AR) antagonist candidate, PORT-6, in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
  • “We are excited to announce the first patient dosed in the Phase 1a safety portion of the ADPORT-601 trial in collaboration with our academic partners.
  • This trial is a critical next step in our comprehensive exploration of how targeting the adenosine pathway could improve outcomes in multiple cancer types,” said Dr. Ian Walters, CEO and Chairman of Portage Biotech.
  • The trial also plans to evaluate Portage’s adenosine 2B receptor (A2BR) antagonist (PORT-7) and integrate proprietary biomarkers to select patients with high A2A and A2B expression.

nesto raises $80 million Series C financing round to accelerate Canadian expansion and launch nesto Mortgage Cloud

Retrieved on: 
Tuesday, December 13, 2022
Cloud, Series, National bank, Power Corporation of Canada, Bank of Montreal, National Bank of Canada, Montreal, Digital, CO, Organization, Portage, Real estate

MONTREAL, Dec. 13, 2022 (GLOBE NEWSWIRE) -- nesto , Canada’s online mortgage lender, announced today the closing of an oversubscribed $80 million Series C financing.

Key Points: 
  • MONTREAL, Dec. 13, 2022 (GLOBE NEWSWIRE) -- nesto , Canada’s online mortgage lender, announced today the closing of an oversubscribed $80 million Series C financing.
  • The Series C financing round will enable nesto to further develop its proprietary technology, expand its marketing capabilities across Canada and launch nesto Mortgage Cloud .
  • nesto is Canada’s leading digital mortgage lending platform, with a dedicated team of qualified mortgage experts supported by advanced technologies.
  • nesto is delivering on this mission by offering Canadians a leading digital mortgage experience and by empowering partner mortgage lenders to improve and streamline their mortgage lending operations with the nesto Mortgage Cloud.

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Retrieved on: 
Tuesday, November 29, 2022
MSD, Merck Sharp & Dohme Federal Credit Union, Society for Immunotherapy of Cancer, ASCO, PRTG, NSCLC, Nature, Fiscal, Quarter, Safety, Insurance, Therapy, Policy, Patient, Acquisition, CRADA, Society, Immunotherapy, American Society of Clinical Oncology, Pembrolizumab, Portage, News, Cancer, SITC, Research, Intellectual property, Development, Quality of life, Clinical trial, Survival, Research and development, IPhone XR, Pharmaceutical industry, Renewable energy, Medical device, Bank, Health insurance, Taro (river), Merck

WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.

Key Points: 
  • WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.
  • Research & development costs increased by approximately $0.2 million, or approximately 15%, from approximately $1.3 million in the Fiscal 2022 Quarter, to approximately $1.5 million in the Fiscal 2023 Quarter.
  • Additionally, the Company incurred payroll-related expenses of $0.5 million in Fiscal 2023 Quarter, compared to $0.2 million in the Fiscal 2022 Quarter.
  • General and administrative expenses increased by approximately $0.1 million, or approximately 5%, from approximately $2.0 million in the Fiscal 2022 Quarter, to approximately $2.1 million in the Fiscal 2023 Quarter.

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Quality of life, GLOBE, Nature, PRTG, Society for Immunotherapy of Cancer, Tumor microenvironment, B cell, Immunotherapy, Cytokine, Merck, Neoplasm, Society, Portage, Large-cell lung carcinoma, ASCO, NASDAQ, News, Safety, PD-1, University, Survival, Company, Cancer, Pembrolizumab, Poster, American Society of Clinical Oncology, Patient, Immune system, NSCLC, Therapy, Blood, SITC, Pharmaceutical industry, EU

The data builds on previous results shared at the 2022 American Society of Clinical Oncology (ASCO) meeting in June.

Key Points: 
  • The data builds on previous results shared at the 2022 American Society of Clinical Oncology (ASCO) meeting in June.
  • We continue to see single agent activity of PORT-2 at the 3 mg/m2 dose, which is the mid-dose level in our study.
  • Portage is a clinical-stage immuno-oncology company advancing first-in-class therapies to improve long-term treatment response and quality of life in patients with evasive cancers.
  • For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech or find us on LinkedIn atPortage Biotech Inc.

Canada supports Dakota Tipi First Nation in undertaking research and commemoration activities around five former residential school sites

Retrieved on: 
Tuesday, January 18, 2022
First Nations nutrition experiments, Archive, Research, National Indian Youth Council, News, Portage, Government, Library and Archives Canada, Survivor, Portage la Prairie, National Centre for Truth and Reconciliation, Indigenous self-government in Canada, Truth commission, Population, Fort Alexander, Minister of Crown–Indigenous Relations, Indigenous peoples, History, Time, Community Support Group, Hope, Reconciliation, Residential school, First Nations, Child, Investment, Medicine, Oil, Environmental remediation, Crown

A National Indian Residential School Crisis Line is available to provide support to former residential school students who can access emotional and crisis referral services by calling the 24-Hour National Crisis Line at 1-866-925-4419.

Key Points: 
  • A National Indian Residential School Crisis Line is available to provide support to former residential school students who can access emotional and crisis referral services by calling the 24-Hour National Crisis Line at 1-866-925-4419.
  • The locating of unmarked graves at former residential school sites across Canada is a tragic reminder of the abuse Indigenous children suffered in these institutions.
  • Dakota Tipi First Nation will also undertake knowledge gathering and with direction from Elders, Survivors and their families explore commemoration and memorialization activities.This will be a community-led process to ensure Dakota Tipi First Nation can undertake this work in a way that respects their Dakota protocols.
  • The Government of Canada and all Canadians support the Residential School Survivor Project, which will be guided by a Survivor-led steering committee - to contribute to the healing of Survivors and community of Dakota Tipi First Nation."

Stryker declares a $0.695 per share quarterly dividend

Retrieved on: 
Thursday, December 9, 2021
NYSE, Environment, Board, Neurotechnology, Board of directors, Spine, GLOBE, SYK, Stryker, Management

Kalamazoo, Michigan, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.695 per share payable January 31, 2022 to shareholders of record at the close of business on December 31, 2021, representing an increase of 10.3% versus the prior year and previous quarter.

Key Points: 
  • Kalamazoo, Michigan, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.695 per share payable January 31, 2022 to shareholders of record at the close of business on December 31, 2021, representing an increase of 10.3% versus the prior year and previous quarter.
  • Despite a challenging environment, we continue to deliver strong sales growth and drive solid financial results, and consistent with our stated capital allocation philosophy, we are raising our dividend 10.3%, said Kevin Lobo, Chair and Chief Executive Officer.
  • Stryker is one of the worlds leading medical technology companies and, together with its customers, is driven to make healthcare better.
  • The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.